R. Mascari

483 total citations
14 papers, 368 citations indexed

About

R. Mascari is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, R. Mascari has authored 14 papers receiving a total of 368 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Immunology, 7 papers in Oncology and 6 papers in Molecular Biology. Recurrent topics in R. Mascari's work include Immunotherapy and Immune Responses (8 papers), CAR-T cell therapy research (7 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). R. Mascari is often cited by papers focused on Immunotherapy and Immune Responses (8 papers), CAR-T cell therapy research (7 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). R. Mascari collaborates with scholars based in United States and United Kingdom. R. Mascari's co-authors include John M. Kirkwood, Joseph G. Ibrahim, Theresa L. Whiteside, Michael B. Atkins, David H. Lawson, Donna M. Morrissey, Sanjiv S. Agarwala, Paul B. Chapman, Stewart Sell and Thomas J. Richards and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Immunology and Cancer.

In The Last Decade

R. Mascari

14 papers receiving 351 citations

Peers

R. Mascari

IMMUN

ONCOL

MB

RNMI

GENET

V. Waldmann Germany

Karin M. Greulich‐Bode Germany

Maria Teresa Melucci Italy

Matthew N. Harris United States

Bridget Finnerty United States

Daniel Schulz Switzerland

Debra M. Krupke United States

Daniele Tavernari Switzerland

Dieter Naeher Switzerland

Laura M Drogowski United States

V. Waldmann Germany

R. Mascari

160 ×0.7

IMMUN

274 ×1.2

ONCOL

284 ×1.8

MB

28 ×0.6

RNMI

30 ×1.0

GENET

Citations per year, relative to R. Mascari R. Mascari (= 1×) peers V. Waldmann

Countries citing papers authored by R. Mascari

Since Specialization

Citations

This map shows the geographic impact of R. Mascari's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Mascari with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Mascari more than expected).

Fields of papers citing papers by R. Mascari

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. Mascari. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Mascari. The network helps show where R. Mascari may publish in the future.

Co-authorship network of co-authors of R. Mascari

This figure shows the co-authorship network connecting the top 25 collaborators of R. Mascari. A scholar is included among the top collaborators of R. Mascari based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Mascari. R. Mascari is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

1.

Sobol, Robert W., Hussein A. Tawbi, D.M. Jukic, et al.. (2006). Mismatch repair (MMR) and base excision repair (BER) protein expression correlates with clinical response to dacarbazine (DTIC)/temozolomide (TMZ) therapy of patients with metastatic melanoma. Journal of Clinical Oncology. 24(18_suppl). 8015–8015. 5 indexed citations

2.

Kirkwood, John M., Stephanie R. Land, Cindy Sander, et al.. (2004). E1696: Final analysis of the clinical and immunological results of a multicenter ECOG phase II trial of multi-epitope peptide vaccination for stage IV melanoma with MART-1 (27–35), gp100 (209–217, 210M), and tyrosinase (368–376, 370D) (MGT) +/- IFNα2b and GM-CSF. Journal of Clinical Oncology. 22(14_suppl). 7502–7502. 1 indexed citations

3.

Kirkwood, John M., et al.. (2004). E1696: Final analysis of the clinical and immunological results of a multicenter ECOG phase II trial of multi-epitope peptide vaccination for stage IV melanoma with MART-1 (27–35), gp100 (209–217, 210M), and tyrosinase (368–376, 370D) (MGT) +/- IFNα2b and GM-CSF. Journal of Clinical Oncology. 22(14_suppl). 7502–7502. 12 indexed citations

4.

Kirkwood, John M., Thomas J. Richards, Hassane M. Zarour, et al.. (2002). Immunomodulatory effects of high‐dose and low‐dose interferon α2b in patients with high‐risk resected melanoma. Cancer. 95(5). 1101–1112. 73 indexed citations

5.

Kirkwood, John M., Joseph G. Ibrahim, David H. Lawson, et al.. (2001). High-Dose Interferon Alfa-2b Does Not Diminish Antibody Response to GM2 Vaccination in Patients With Resected Melanoma: Results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696. Journal of Clinical Oncology. 19(5). 1430–1436. 101 indexed citations

6.

Kirkwood, John M., R. Mascari, Howard Edington, et al.. (2000). Analysis of therapeutic and immunologic effects of R24 anti-GD3 monoclonal antibody in 37 patients with metastatic melanoma. Cancer. 88(12). 2693–2702. 33 indexed citations

7.

Palmer, Kay, J. Moore, Robert C. Rees, et al.. (1999). Gene Therapy with Autologous, Interleukin 2-Secreting Tumor Cells in Patients with Malignant Melanoma. Human Gene Therapy. 10(8). 1261–1268. 66 indexed citations

8.

Shafer, Steven A., et al.. (1996). Automatic multiparameter fluorescence imaging for determining lymphocyte phenotype and activation status in melanoma tissue sections. Cytometry. 25(1). 71–81. 17 indexed citations

9.

Shafer, Steven A., et al.. (1996). Automatic multiparameter fluorescence imaging for determining lymphocyte phenotype and activation status in melanoma tissue sections. Cytometry. 25(1). 71–81. 6 indexed citations

10.

Wang, Yi‐Ping, Uma Rao, R. Mascari, et al.. (1996). Molecular analysis of melanoma precursor lesions.. PubMed. 7(12). 1733–40. 21 indexed citations

11.

Kirkwood, John M., Daniel R. Vlock, Richard P. Day, et al.. (1992). A PHASE IB TRIAL OF MURINE MONOCLONAL ANTIBODY R24 (ANTI-GD3) IN METASTATIC MELANOMA. Journal of Immunotherapy. 11(2). 130–130. 2 indexed citations

12.

Sell, Stewart, et al.. (1970). Studies on rabbit lymphocytes in vitro. 13. The induction of blast transformation with the F (ab')2 and Fab fragments of anti-lymphocytic, anti-IgG and anti-allotypic globulins.. PubMed. 105(6). 1400–5. 17 indexed citations

13.

Sell, Stewart, R. Mascari, & Peter Goldblatt. (1970). The in Vitro Effects of Goat Antisera to Rabbit Thymocyte Subcellular Fractions. The Journal of Immunology. 105(6). 1569–1574. 4 indexed citations

14.

Sell, Stewart, et al.. (1970). Studies on Rabbit Lymphocytes in Vitro. The Journal of Immunology. 105(6). 1400–1405. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact